Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Global health experts have united in a call for governments and international organisations around the world to plan strategically for the coordinated production, equitable distribution and surveillance of COVID-19 medical products to ensure access to quality-assured medications for everyone.

Coronavirus close-up © NIH

The comment piece, published in The Lancet Global Health, was signed by 55 signatories from across 20 countries.

Enormous emergency efforts are underway to find optimal medical products, to prevent, diagnose, and treat COVID-19, which approximately 7.8 billion people will depend on. With significant disruption of pharmaceutical production and supply, and increasing numbers of falsified and substandard products, strategic planning is needed now to ensure global access to quality-assured medical products and monitoring of supply chains.

Co-author Professor Paul Newton, who leads Medicine Quality at IDDO, said: ‘Vital interventions are needed to ensure global manufacture, access, protection, and monitoring of supply chains.

The full story is available on the IDDO website

Similar stories

COPCOV now world’s largest COVID-19 pre-exposure prophylaxis trial

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

Researchers call for access to Ivermectin for young children

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

The COPCOV Trial’s position statement on “A living WHO guideline on drugs to prevent COVID-19.”

Following WHO recommendations against the use of hydroxychloroquine in the prevention of COVID-19, including its use in controlled trials, we are reviewing the guideline and available evidence. We are concerned that this judgement from the authors of the guideline is scientifically unsound.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.